Supplementary Video 4-F5.mp4 (1.72 MB)

Supplementary Video 4-F5: Cytotoxic T lymphocytes targeting a conserved SARS-CoV-2 spike epitope are efficient serial killers

media

posted on 17.03.2022, 13:51 by Daniel Meyer, Mohsen Fathi, Lindsey Charley, Laurence Cooper, Navin Varadarajan

Supplementary Video S4: Representative TIMING Videos displaying single nanowells containing killer or non-killer T cells with differences in IFNγ secretion.

Funding

NV was supported by the NIH (R01GM143243), CPRIT (RP180466), MRA Established Investigator Award (509800), NSF (1705464), CDMRP (CA160591), and Owens foundation. DDM, NV, MF, LC and LJNC have equity ownership in CellChorus. LJNC receives royalties from Bristol Myers Squibb (via City of Hope National Medical Center) and Immatics (via MD Anderson Cancer Center), holds receipts of intellectual property rights from Sangamo BioSciences, MD Anderson Cancer Center, and Ziopharm Oncology, and also has equity ownership interest in Targazyme, Ziopharm Oncology, Immatics, Secure Transfusion Services, AuraVax Therapeutics, and IterateBio. NV has equity ownership in AuraVax Therapeutics and owns intellectual property rights from UH.

History

Usage metrics

Read the peer-reviewed publication

Cytotoxic T lymphocytes targeting a conserved SARS-CoV-2 spike epitope are efficient serial killers

BioTechniques

Keywords

SARS-CoV-2 Covid-19 time-lapse imaging cytotoxicity cytokines single-cell T cells lymphocytes

Licence

CC BY-NC-ND 4.0